At what enterprise value was SINTETICA acquired in 2019?

You can find the full valuation details of SINTETICA on mynth capital. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 15.6x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of SINTETICA when it was acquired by ARDIAN?

The exact EV/EBITDA multiple for SINTETICA is available on mynth capital. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 15.6x. Join our community for free to access full valuation data and industry trends.

When was SINTETICA acquired by ARDIAN?

SINTETICA was acquired by ARDIAN in 2019.

What was the revenue of SINTETICA at the time of the deal?

The revenue of SINTETICA at the time of the deal is estimated to be in the range of 50M - 100M CHF. Register for free to access the full transaction report and exact valuation multiples.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the SINTETICA acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the SINTETICA deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.ardian.com/sites/default/files/2020-04/CP-SINTETICA-20190523-EN.pdf

← DATABASE

Home Database Healthcare & PharmaSINTETICA

05/2019

SINTETICA acquired by ARDIAN

SWITZERLAND Life Sciences / Pharma & Biotech REV 50M - 100M CHF

Context

Ardian acquired a majority stake in Sintetica from the majority shareholder Daphne and the owner family. The transaction was structured as a partnership, with the existing shareholders and management team reinvesting via a significant minority stake to maintain continuity. At the time of the deal, Sintetica was in a phase of hyper-growth (31% CAGR between 2016-2018). Ardian's investment was designed to accelerate the company's internationalization—expanding its reach beyond the 45 countries it already served—and to fuel R&D for new patented, "ready-to-use" drug delivery systems that optimize hospital efficiency and patient safety.

SINTETICA, which reported an EBITDA margin of in 2018, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the Healthcare & Pharma sector (15.6x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Sintetica is a long-standing Swiss pharmaceutical company specializing in the research, manufacturing, and marketing of high-quality sterile injectable solutions. Its portfolio focuses on innovative "ready-to-use" formulations for local anesthesia and pain management, specifically designed to reduce opioid reliance and support the global trend of ambulatory (one-day) surgery.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (CHF)

Year

Rev

EBITDA

EBIT

2018

2017

Similar deals in Life Sciences

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
07/2019	3I	IONISOS	FRANCE	CDMO
07/2019	PERMIRA	QUOTIENT SCIENCES	UNITED KINGDOM	CDMO
04/2019	EURAZEO	D.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER)	NETHERLANDS	Medical Devices
04/2019	ICG / MERIEUX EQUITY PARTNERS	DOC GENERICI	ITALY	Generics / Labs
12/2018	MERCK & CO.	ANTELLIQ	FRANCE	Animal Health
11/2018	ARDIAN	NEOPHARMED GENTILI	ITALY	Generics / Labs
10/2018	BRIDGEPOINT	HTL BIOTECHNOLOGY	FRANCE	CDMO
10/2018	ASTORG	NEMERA	FRANCE	Medical Consumables
10/2018	ARDIAN	INULA GROUP	BELGIUM	Pharma & Biotech
08/2018	DENTRESSANGLE	ACTEON	FRANCE	Medical Devices

REFERENCES

Revenue range: 50M - 100M CHF

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of SINTETICA by ARDIAN are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Press release: view release

Acquirer: ardian